AU2011275393B2 - Piperidinyl pyrimidine amides as Kv7 potassium channel openers - Google Patents

Piperidinyl pyrimidine amides as Kv7 potassium channel openers Download PDF

Info

Publication number
AU2011275393B2
AU2011275393B2 AU2011275393A AU2011275393A AU2011275393B2 AU 2011275393 B2 AU2011275393 B2 AU 2011275393B2 AU 2011275393 A AU2011275393 A AU 2011275393A AU 2011275393 A AU2011275393 A AU 2011275393A AU 2011275393 B2 AU2011275393 B2 AU 2011275393B2
Authority
AU
Australia
Prior art keywords
depression
disorder
disorders
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011275393A
Other languages
English (en)
Other versions
AU2011275393A1 (en
Inventor
Michelle Marie Claffey
Jennifer Elizabeth Davoren
John Adams Lowe Iii
Robert Joseph Mather
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2011275393A1 publication Critical patent/AU2011275393A1/en
Application granted granted Critical
Publication of AU2011275393B2 publication Critical patent/AU2011275393B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2011275393A 2010-07-08 2011-06-20 Piperidinyl pyrimidine amides as Kv7 potassium channel openers Ceased AU2011275393B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36250510P 2010-07-08 2010-07-08
US61/362,505 2010-07-08
PCT/IB2011/052686 WO2012004698A1 (en) 2010-07-08 2011-06-20 Piperidinyl pyrimidine amides as kv7 potassium channel openers

Publications (2)

Publication Number Publication Date
AU2011275393A1 AU2011275393A1 (en) 2013-01-10
AU2011275393B2 true AU2011275393B2 (en) 2014-04-10

Family

ID=44487037

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011275393A Ceased AU2011275393B2 (en) 2010-07-08 2011-06-20 Piperidinyl pyrimidine amides as Kv7 potassium channel openers

Country Status (11)

Country Link
US (1) US8883812B2 (https=)
EP (1) EP2590961A1 (https=)
JP (1) JP5763758B2 (https=)
KR (1) KR101449348B1 (https=)
CN (1) CN102971307A (https=)
AU (1) AU2011275393B2 (https=)
CA (1) CA2804165C (https=)
MX (1) MX2013000138A (https=)
SG (1) SG186409A1 (https=)
WO (1) WO2012004698A1 (https=)
ZA (1) ZA201300499B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014145852A2 (en) 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
SMT202300362T1 (it) * 2014-09-12 2023-11-13 Biohaven Therapeutics Ltd Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7
EP4241843B1 (en) * 2018-02-20 2025-05-21 H. Lundbeck A/S Alcohol derivatives as kv7 potassium channel openers
SG11202008030WA (en) 2018-03-19 2020-10-29 Knopp Biosciences Llc Kv7 channel activators compositions and methods of use
AR119521A1 (es) * 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
BR112022004847A2 (pt) * 2019-09-17 2022-06-07 Knopp Biosciences Llc Método para tratar uma doença ou distúrbio de neurodesenvolvimento
WO2021119018A1 (en) * 2019-12-09 2021-06-17 The Board Of Trustees Of The Leland Stanford Junior University A method to improve sleep quality in the elderly by controlling excitability of hypocretin neurons
WO2021211867A1 (en) * 2020-04-16 2021-10-21 Attune Neurosciences, Inc. Kv7 modulators for treating sleep or anxiety disorders
BR112023003624A2 (pt) * 2020-08-28 2023-03-28 Pfizer Ferramenta de suporte à decisão computadorizada e dispositivo médico para monitoramento e cuidado de condição respiratória
GB202306914D0 (en) * 2023-05-10 2023-06-21 Sania Rx Ltd Method
CN119661413B (zh) * 2024-12-28 2025-06-24 齐鲁医药学院 Kv7钾离子通道开放剂及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064277A1 (en) * 2004-12-17 2006-06-22 Takeda Cambridge Limited Silicon compounds and their use
US20070066612A1 (en) * 2005-09-09 2007-03-22 Nikolay Khanzhin Substituted pyrimidine derivatives
WO2008024398A2 (en) * 2006-08-23 2008-02-28 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US20080318979A1 (en) * 2007-06-13 2008-12-25 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032233A3 (cs) * 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
US7322249B2 (en) 2005-07-07 2008-01-29 Delphi Technologies, Inc. Mounting for a probe sensor
KR20080043314A (ko) * 2005-09-09 2008-05-16 하. 룬트벡 아크티에 셀스카브 피리미딘 유도체 및 ｋｃｎｑ 포타슘 채널 개방제로서의그의 용도
TWI453013B (zh) 2006-02-07 2014-09-21 Lundbeck & Co As H N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
AR070513A1 (es) 2007-08-01 2010-04-14 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064277A1 (en) * 2004-12-17 2006-06-22 Takeda Cambridge Limited Silicon compounds and their use
US20070066612A1 (en) * 2005-09-09 2007-03-22 Nikolay Khanzhin Substituted pyrimidine derivatives
WO2008024398A2 (en) * 2006-08-23 2008-02-28 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US20080318979A1 (en) * 2007-06-13 2008-12-25 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators

Also Published As

Publication number Publication date
ZA201300499B (en) 2013-09-25
KR101449348B1 (ko) 2014-10-08
CA2804165C (en) 2015-02-24
US8883812B2 (en) 2014-11-11
SG186409A1 (en) 2013-02-28
US20130150391A1 (en) 2013-06-13
KR20130031323A (ko) 2013-03-28
WO2012004698A1 (en) 2012-01-12
JP5763758B2 (ja) 2015-08-12
EP2590961A1 (en) 2013-05-15
MX2013000138A (es) 2013-03-05
AU2011275393A1 (en) 2013-01-10
JP2013531006A (ja) 2013-08-01
CA2804165A1 (en) 2012-01-12
CN102971307A (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
AU2011275393B2 (en) Piperidinyl pyrimidine amides as Kv7 potassium channel openers
EP3423443B1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
CN102933564B (zh) 用作β-分泌酶(BACE)抑制剂的5,6-二氢-2H-[1,4]噁嗪-3-基-胺衍生物
AU2015355841B2 (en) Heterocyclic derivatives and use thereof
EP3150592B1 (en) Alk kinase inhibitor, and preparation method and use thereof
CN104284657A (zh) 用于抑制RORγ活性和治疗疾病的双环砜化合物
JP2021521266A (ja) 疾患の処置のためのｋｄｍ１ａ阻害剤
MX2014014911A (es) Análogos de alcoxi pirazol bicíclico sustituido como moduladores alostéricos de receptores de mglur5.
JP2012529442A (ja) ビシクロ置換ピラゾロン−アゾ誘導体の塩、その製造方法及びその使用
AU2020207162B2 (en) (2,5-Dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases
BRPI0911990A2 (pt) compostos de piridina prolinamida e seu uso na terapia
CA2792918A1 (en) Benzazepine compound
CA2809217A1 (en) Pyrimidones for treatment of potassium channel related diseases
JP2023515101A (ja) 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
EP4587429A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
WO2006126541A1 (ja) ビタミンｋ類含有医薬組成物
HK1177199A (en) Piperidinyl pyrimidine amides as kv7 potassium channel openers
EP3930712A1 (en) Imidazolopyrazine compounds for ire1 inhibition
PT1682523E (pt) Derivados de morfolina como inibidores da recaptação de norepinefrina
CA3059687A1 (en) Amide derivatives as nav1.7 and nav1.8 blockers
HK1209284B (zh) 嘧啶基酪氨酸激酶抑制劑

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired